JAKARTA - SOE Minister Erick Thohir asked the domestic SOEs' COVID-19 Vaccine production capacity to be doubled to support Indonesia's role as a world vaccine production hub.
"The total production could be up to 500 million doses. If necessary, increase it when Indonesia becomes the world's vaccine production hub. We will increase it," said Erick Thohir, quoted from Antara, Thursday, June 9.
The BUMN vaccine with a sub-unit recombinant protein platform was developed in collaboration with PT Bio Farma, Baylor College of Medicine and Eijkman.
Currently, the vaccine has completed two stages of clinical trials, in the form of providing production facilities to standard Good Manufacturing Practices (GMP) procedures or good production methods according to regulations.
In the final clinical trial, which is expected to run until July 2022, BUMN Vaccines conducted a study of 4,050 subjects with an age limit of 18-70 years to measure safety for primary, booster and child vaccination needs.
"We hope that this third clinical trial will pass for the premier vaccine. It is hoped that the government can use it as a booster vaccine," he said.
In the early stages of production, said Erick, it is prioritized for domestic needs of 120 million doses. The production can be expanded to 500 million doses to support Indonesia's role as a world vaccine hub.
Regarding the naming of the BUMN Vaccine, Erick said it was for the initial need in the form of registering the name of the vaccine during the clinical trial process in Indonesia.
"The name of the BUMN vaccine, in the future we will consult with the president, whether the name of this vaccine will be changed. Because in including the name, it does not mean we are arrogant, as if claiming this belongs to a certain group, because at the beginning we have to register it," he said.
As is known, there are currently four COVID-19 vaccines that are being prepared for domestic production. In addition to the BUMN Vaccine, there is also the Red and White Vaccine developed by Airlangga University researchers with PT Biotis, the Red and White Vaccine PT Bio Farma and Boulevard Medicine.
In addition, there is also the Zifivax Vaccine which was developed by PT JBio through technology transfer from Anhui Zhifei Longco, China, for the development of a sub-unit recombinant protein platform vaccine. In addition to the COVID-19 vaccine, other vaccines will be produced, such as Meningitis, Measles Rubella, TB and HPV.
At that time, the Zifivax Vaccine had entered the physical construction stage and procured production equipment to meet the fill-finished production target in September-December 2022.
Another domestic vaccine is Etana in collaboration with Yuxi Walvax, China, for the production of the first mRNA platform COVID-19 vaccine in Indonesia.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
